PAION Announces Phase I Study With Sedative/Anaesthetic CNS 7056 Progressed to Midazolam Comparison AACHEN, Germany and CAMBRIDGE, UK, Sept. 22, 2008 (GLOBE NEWSWIRE) -- The biopharmaceutical company PAION AG (ISIN DE000A0B65S3) (Frankfurt:PA8) (London AIM: PAI) today announces that its Phase I...

Interim Results: PAION AG Reports Half-year Results 2008 and Provides Strategy Update AACHEN, Germany, Aug. 11, 2008 (PRIME NEWSWIRE) -- The biopharmaceutical company PAION AG (ISIN DE000A0B65S3) (Frankfurt:PA8) (London AIM:PAI) today announced its financial results according to...

PAION's Anticoagulant Solulin Successfully Tested in First-in-man Study AACHEN, Germany, Feb. 28, 2008 (PRIME NEWSWIRE) -- The biopharmaceutical company PAION AG (Frankfurt:PA8) (Prime Standard) today announced that its drug candidate Solulin has been successfully tested...

PAION GmbH Awarded Euro $4.9 Million Grant for the Development of Protein Production Capabilities AACHEN, Germany, June 27, 2002 (PRIMEZONE) -- PAION GmbH today announced a Euro 4.9 million grant, awarded over a period of four years, by the State of North Rhine-Westphalia for the development of...